Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00571493 | VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 42 | University of NebraskaOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT00610883 | LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma | completed | Phase 2 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT03571308 | A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)(ACCEPT) | completed | Phase 1 / Phase 2 | 39 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT00550615 | Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 38 | University of NebraskaOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT03155100 | Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines(KEd) | completed | Phase 2 | 15 | Raija SilvennoinenOTHER | 2 | Sep 26, 2023 | clinicaltrials |
| NCT01336933 | Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma | completed | Phase 2 | 34 | University of NebraskaOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT01739309 | Study of LY2835219 for Mantle Cell Lymphoma | completed | Phase 2 | 28 | Eli Lilly and CompanyINDUSTRY | 2 | Sep 21, 2023 | clinicaltrials |
| NCT02661035 | Allo HSCT Using RIC for Hematological Diseases | completed | Phase 2 | 156 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03202628 | Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 8 | Mayo ClinicOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03309878 | Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma | completed | Phase 1 / Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2023 | clinicaltrials |
| NCT01696461 | A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor | completed | Phase 2 | 127 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Sep 14, 2023 | clinicaltrials |
| NCT05082675 | Stem Cell Translpantation in Multiple Myeloma | completed | Phase 2 | 357 | European Society for Blood and Marrow TransplantationNETWORK | 11 | Sep 11, 2023 | clinicaltrials |
| NCT01346787 | Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients(CCD) | completed | Phase 2 | 58 | European Myeloma Network B.V.NETWORK | 2 | Sep 8, 2023 | clinicaltrials |
| NCT01882803 | A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma(DYNAMO) | completed | Phase 2 | 129 | SecuraBioINDUSTRY | 12 | Sep 7, 2023 | clinicaltrials |
| NCT02962401 | Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia(RemodelWM3) | completed | Phase 2 | 50 | French Innovative Leukemia OrganisationOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT02597062 | High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma | completed | Phase 2 | 76 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 28, 2023 | clinicaltrials |
| NCT03542266 | CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma | completed | Phase 2 | 21 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 22, 2023 | clinicaltrials |
| NCT04445701 | Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 10 | Arch OncologyINDUSTRY | 1 | Aug 22, 2023 | clinicaltrials |
| NCT01484093 | Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 96 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 16, 2023 | clinicaltrials |
| NCT03010358 | Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 24 | Alexey Danilov, MDOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT01145989 | A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 8 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT01652144 | A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma | completed | Phase 2 | 12 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03215524 | A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide(DCDP) | completed | Phase 2 | 120 | Canadian Myeloma Research GroupOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03702231 | Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I) | completed | Phase 2 | 116 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Aug 4, 2023 | clinicaltrials |
| NCT01267812 | Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation | completed | Phase 2 | 23 | City of Hope Medical CenterOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT02576990 | Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) | completed | Phase 2 | 80 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 27, 2023 | clinicaltrials |
| NCT03959358 | A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders | completed | Phase 2 | 10 | University Health Network, TorontoOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT01203020 | Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation | completed | Phase 2 | 22 | West Virginia UniversityOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT02185820 | Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)(CPD) | completed | Phase 1 / Phase 2 | 57 | European Myeloma Network B.V.NETWORK | 1 | Jul 3, 2023 | clinicaltrials |
| NCT02204241 | Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients(CCD) | completed | Phase 1 / Phase 2 | 36 | European Myeloma Network B.V.NETWORK | 1 | Jul 3, 2023 | clinicaltrials |
| NCT01160107 | Revlimid And Prednisone Followed By Revlimid, Melphalan And Prednisone In Multiple Myeloma Patients(RP_MPR) | completed | Phase 2 | 46 | Fondazione EMN Italy OnlusOTHER | 0 | Jun 29, 2023 | clinicaltrials |
| NCT01166113 | Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide(PCP) | completed | Phase 1 / Phase 2 | 67 | Fondazione EMN Italy OnlusOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT01572662 | Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning | completed | Phase 2 | 201 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT02226965 | PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine) | completed | Phase 2 | 45 | Sierra Oncology LLC - a GSK companyINDUSTRY | 2 | Jun 29, 2023 | clinicaltrials |
| NCT01348919 | Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 11 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 2 | Jun 28, 2023 | clinicaltrials |
| NCT01754857 | Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL | completed | Phase 2 | 36 | University of Wisconsin, MadisonOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT03364231 | Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma | completed | Phase 2 | 21 | TG Therapeutics, Inc.INDUSTRY | 1 | Jun 23, 2023 | clinicaltrials |
| NCT01733238 | Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 13 | Sierra Oncology LLC - a GSK companyINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02030834 | Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas | completed | Phase 2 | 63 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02797964 | A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer | completed | Phase 1 / Phase 2 | 107 | Sierra Oncology LLC - a GSK companyINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT03944057 | A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma(MARCH) | completed | Phase 2 | 82 | Antengene CorporationINDUSTRY | 1 | Jun 15, 2023 | clinicaltrials |
| NCT02903381 | A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma | completed | Phase 2 | 8 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT02279394 | E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma | completed | Phase 2 | 51 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT05380635 | PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma | completed | Phase 2 | 9 | SoligenixINDUSTRY | 1 | Jun 7, 2023 | clinicaltrials |
| NCT00224393 | Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis | completed | Phase 2 | 60 | The Cleveland ClinicOTHER | 0 | May 30, 2023 | clinicaltrials |
| NCT01264315 | Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant | completed | Phase 2 | 53 | Fondazione EMN Italy OnlusOTHER | 1 | May 26, 2023 | clinicaltrials |
| NCT04121507 | ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy | completed | Phase 2 | 60 | GWT-TUD GmbHOTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT00071071 | Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin. | completed | Phase 2 | 25 | GenmabINDUSTRY | 1 | May 18, 2023 | clinicaltrials |
| NCT02416206 | High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma | completed | Phase 2 | 65 | Northside Hospital, Inc.OTHER | 1 | May 18, 2023 | clinicaltrials |
| NCT00896493 | Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma | completed | Phase 2 | 38 | Stanford UniversityOTHER | 1 | May 11, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Sep 28, 2023source: clinicaltrials